Digital Market Outlook: UK eHealth solutions for diabetes segment ARPU 2020

The graph presents the eHealth solutions for diabetes segment ARPU in the United Kingdom in 2014 and 2015, and provides a forecast thereof until 2020. Average revenue per user in the eHealth diabetes segment is expected to grow from 17.8 U.S. dollars in 2014 to 134 U.S. dollars in 2020. An overview of all Digital Markets can be found here.
Statista’s Digital Market Outlook offers forecasts, detailed market insights and essential performance indicators of the most significant areas in the “Digital Economy”, including various digital goods and services. Alongside revenue forecasts for 50 countries worldwide, Statista offers additional insights into consumer trends and demographic structure of digital consumer markets.

Average revenue per user (ARPU) of eHealth solutions for diabetes in the United Kingdom (UK) from 2014 to 2020 (in U.S. dollars)

Characteristic	ARPU in U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

February 2016

More information

Region

United Kingdom

Survey time period

2015

Supplementary notes

* Estimate.

The Diabetes segment includes the user and revenue development for three eHealth product categories for people with diabetes: (1) connected medical devices designed for diabetes patients to use at home (Smart Devices), (2) digital diabetes applications for smartphone and/or tablets (Apps) and (3) telemedical services for diabetes patients (Telemedical Services). Hardware and software solutions for healthcare professionals, e.g. medical equipment for hospitals and doctors’ surgeries are not included.

The Smart Devices segment covers medical diabetes devices (hardware) which are equipped with dedicated interfaces or SIM cards that serve to transmit measurement data across a wireless connection (e.g. via mobile networks, WiFi, bluetooth, M2M technologies, NFC, BLE). For example, connected glucose meters, systems for continuous glucose monitoring (CGMs) or connected insulin injection devices (e.g. Telcare, Freestyle Libre from Abbott or the MiniMed Veo Insulin Pump from Medtronic). The measurement data can be sent to a smartphone and be synchronized with an app or, when there is an increased need for monitoring, the data can also be sent to a telemedical service center. Depending on the measuring system, additional hardware revenues can fall under this market segment if additional reading or transmitting devices are implemented.
Further information on methodology can be found here.

Citation formats